MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
1.350
+0.060
+4.65%
After Hours: 1.329 -0.021 -1.57% 18:15 12/04 EST
OPEN
1.290
PREV CLOSE
1.290
HIGH
1.370
LOW
1.255
VOLUME
378.42K
TURNOVER
--
52 WEEK HIGH
9.79
52 WEEK LOW
0.9657
MARKET CAP
14.53M
P/E (TTM)
-0.4946
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHIO last week (1124-1128)?
Weekly Report · 4d ago
Phio Pharmaceuticals Completes Enrollment for PH-762 Trial
TipRanks · 11/25 21:27
Phio Pharmaceuticals Completes Enrollment In Phase 1b Trial Of PH-762 siRNA Cancer Therapy
Benzinga · 11/25 16:33
Phio Pharmaceuticals Completes Phase 1b Enrollment for PH-762 Skin Cancer Trial
Reuters · 11/25 16:31
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
Newsfile · 11/25 16:30
Phio Pharmaceuticals CEO Robert J. Bitterman Reports Acquisition of Common Shares
Reuters · 11/24 17:54
Weekly Report: what happened at PHIO last week (1117-1121)?
Weekly Report · 11/24 10:01
Phio Pharmaceuticals files to sell 11.76M shares of common stock for holders
TipRanks · 11/20 21:11
More
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.